A shocking revelation has come to light: despite clear safety warnings, a significant number of older Americans with dementia are being prescribed potentially dangerous brain-altering drugs. This practice, which has been discouraged for years by clinical guidelines, continues to put vulnerable individuals at risk.
The research, published in JAMA, reveals that one in four Medicare beneficiaries with dementia receives these medications, despite the known risks of falls, confusion, and hospitalization. While there has been a slight decline in prescriptions over the study period, from 20% to 16%, the issue persists, particularly for those with cognitive impairment.
Dr. John N. Mafi, the senior author of the study, highlights the concerning trend: "Over two-thirds of patients receiving these prescriptions lacked a documented clinical indication in 2021. This suggests a high level of potentially harmful and inappropriate prescribing."
The study focused on five drug classes: antidepressants with strong anticholinergic properties, antipsychotics, barbiturates, benzodiazepines, and non-benzodiazepine hypnotics. The findings show that these medications were prescribed to 17% of older adults with normal cognition, 22% of those with cognitive impairment without dementia, and a concerning 25% of the dementia group.
Here's where it gets controversial: prescription trends varied significantly across these drug classes. Benzodiazepines and sleep medications saw a decline, but antipsychotic prescriptions rose, and anticholinergic antidepressants remained steady.
Dr. Annie Yang, who led the study, emphasizes the importance of patient-physician collaboration: "CNS-active prescriptions may be appropriate in some cases, but older patients and their caregivers should actively engage with their doctors to ensure the medications are necessary. When inappropriate, alternative treatments should be considered, and the possibility of tapering or stopping the medication should be explored."
The study's limitations include the lack of Medicare Advantage data and a focus on prescribing prevalence rather than cumulative exposure.
And this is the part most people miss: the study's authors suggest that the quality and safety of care for millions of older Americans can be significantly improved.
So, what do you think? Is this a call to action for better healthcare practices, or are there valid reasons for these prescriptions? Let's discuss in the comments and explore the complexities of this issue further.
